[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604208":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":18,"collaborators":20,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":31,"acronym":32,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":7,"enrollmentInfo":36,"targetDuration":39,"studyType":40,"phases":7,"briefSummary":41,"conditions":42,"keywords":46,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":7},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Clara AVERLANT, Master's degree","CONTACT","07 64 45 38 49","clara.averlant@iplesp.upmc.fr",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Tounes SAIDI","+33 (0) 1 53 94 60 34","tounes.saidi@inserm.fr",{"type":19,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[21,24],{"name":22,"class":23},"INSERM UMR S 1136","OTHER",{"name":25,"class":26},"iPLesp","UNKNOWN","100604208","study-of-the-prevalence-of-transmitted-hiv-1-resistance-viral-diversity-and-cluster-identification-in-patients-at-the-time-of-hiv-1-diagnosis-100604208",false,"NCT07146529","Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis","PRINAVIH","Inclusion Criteria:\n\n* Participant (male or female) aged 18 years or older ;\n* Participant newly diagnosed in the laboratory, for whom mandatory HIV seropositivity reporting to Santé Publique France (SPF) is required ;\n* Participant naïve to all antiretroviral treatments (except PrEP and\u002For post-exposure prophylaxis \\[PEP\\]) ;\n* Participant with an available HIV resistance genotype, including amplification of at least reverse transcriptase and protease ;\n* Participant who has not objected to participating in the study.\n\nExclusion Criteria:\n\n* Participant who objects to the use of their data ;\n* Participant currently on antiretroviral treatment ;\n* Participant subject to legal protection measures (safeguard of justice).","ALL","18 Years",{"count":37,"type":38},30060,"ESTIMATED","1 Day","OBSERVATIONAL","The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1",[43,44,45],"HIV Seropositivity","HIV Drug Resistance","HIV Infections",[47,48,49,50,51,52,53],"Genotyping","HIV-1","HIV drug resistance","Transmitted resistance","Viral diversity","Transmission clusters","Primary infection","NOT_YET_RECRUITING","2025-08-21",{"date":57,"type":58},"2025-08-28","ACTUAL",{"date":60,"type":38},"2025-09",{"date":62,"type":38},"2036-09",{"name":5,"class":6}]